Drug Trial Radar · NCT05203341
Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)
Last checked: Nov 19, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
183
Actual
Start
Feb 21, 2022
Primary completion
Jan 10, 2024
Study completion Feb 21, 2024
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Jan 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of NBI-1065845 compared with placebo in participants with MDD on improving symptoms of depression.
Conditions
- Major Depressive Disorder
Interventions
PlaceboDrug
Matching placebo tablets
NBI-1065845Drug
NBI-1065845 tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Total Montgomery Åsberg Depression Rating Scale (MADRS) Score at Day 28Time frame: Baseline, Day 28
Locations
41 sites in 6 countries. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Birmingham, Alabama
Neurocrine Clinical Site
Huntsville, Alabama
Neurocrine Clinical Site
Riverside, California
Neurocrine Clinical Site
San Diego, California
Neurocrine Clinical Site
San Francisco, California
Neurocrine Clinical Site
Torrance, California
Neurocrine Clinical Site
Hartford, Connecticut
Neurocrine Clinical Site
Palmetto Bay, Florida
Neurocrine Clinical Site
Gaithersburg, Maryland
Neurocrine Clinical Site
Weldon Spring, Missouri
Neurocrine Clinical Site
Columbus, Ohio
Neurocrine Clinical Site
North Canton, Ohio
Neurocrine Clinical Site
Oklahoma City, Oklahoma
Neurocrine Clinical Site
Memphis, Tennessee
Neurocrine Clinical Site
Dallas, Texas
Neurocrine Clinical Site
Houston, Texas
Neurocrine Clinical Site
Draper, Utah
Neurocrine Clinical Site
Plovdiv, Bulgaria
Neurocrine Clinical Site
Rousse, Bulgaria
Neurocrine Clinical Site
Sofia, Bulgaria
Neurocrine Clinical Site
Tsarev Brod, Bulgaria
Neurocrine Clinical Site
Varna, Bulgaria
Neurocrine Clinical Site
Veliko Tarnovo, Bulgaria
Neurocrine Clinical Site
Vratsa, Bulgaria
Neurocrine Clinical Site
Kladno, Czechia
Neurocrine Clinical Site
Pilsen, Czechia
Neurocrine Clinical Site
Prague, Czechia
Neurocrine Clinical Site
Prague, Czechia
Neurocrine Clinical Site
Prague, Czechia
Neurocrine Clinical Site
Bełchatów, Poland
Neurocrine Clinical Site
Chełmno, Poland
Neurocrine Clinical Site
Gdansk, Poland
Neurocrine Clinical Site
Katowice, Poland
Neurocrine Clinical Site
Košice, Slovakia
Neurocrine Clinical Site
Rimavská Sobota, Slovakia
Neurocrine Clinical Site
Trenčín, Slovakia
Neurocrine Clinical Site
Vranov nad Topľou, Slovakia
Neurocrine Clinical Site
Gothenburg, Sweden
Neurocrine Clinical Site
Halmstad, Sweden
Neurocrine Clinical Site
Lund, Sweden
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.